0001689548-23-000162.txt : 20231201 0001689548-23-000162.hdr.sgml : 20231201 20231201163348 ACCESSION NUMBER: 0001689548-23-000162 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231128 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231201 DATE AS OF CHANGE: 20231201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Praxis Precision Medicines, Inc. CENTRAL INDEX KEY: 0001689548 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39620 FILM NUMBER: 231460026 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET, 30TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-300-8460 MAIL ADDRESS: STREET 1: 99 HIGH STREET, 30TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 8-K 1 prax-20231128.htm 8-K prax-20231128
FALSE000168954812/3100016895482023-11-282023-11-28

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 28, 2023

PRAXIS PRECISION MEDICINES, INC.
(Exact name of registrant as specified in its charter)
 
 
Delaware
001-39620
47-5195942
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

Praxis Precision Medicines, Inc.
99 High Street, 30th Floor
Boston, Massachusetts 02110
(Address of principal executive offices, including zip code)
(617) 300-8460
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class 
Trade
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share PRAX The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On November 28, 2023, Praxis Precision Medicines, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to effect a 1-for-15 reverse stock split of its common stock (the “Reverse Stock Split”). The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 28, 2023 (the “Effective Time”).
As a result of the Reverse Stock Split, every 15 shares of the Company’s issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock, subject to the treatment of fractional shares as described below, without any action on the part of the holders thereof. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock.
No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive fractional shares as a result of the Reverse Stock Split will be entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing price per share of the common stock (as adjusted for the Reverse Stock Split) on The Nasdaq Global Select Market on November 28, 2023, the last trading day immediately preceding the Effective Time.
Trading of the Company’s common stock on The Nasdaq Global Select Market commenced on a split-adjusted basis when the market opened on November 29, 2023, under the existing trading symbol “PRAX.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split is 74006W 207.
The foregoing description of the Certificate of Amendment is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K (the “Current Report”) and is incorporated herein by reference.
Item 8.01. Other Information
Updated Unaudited Selected Financial Data
This Current Report provides certain updated selected financial data of the Company for the years ended December 31, 2022 and 2021, the three months ended March 31, 2023 and March 31, 2022, the three and six months ended June 30, 2023 and June 30, 2022 and the three and nine months ended September 30, 2022 and September 30, 2023, as adjusted for the Reverse Stock Split (the “Updated Selected Financial Data”). The Updated Selected Financial Data updates and supplements the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 7, 2023, the unaudited condensed consolidated financial statements included in its Quarterly Report on Form 10-Q for the three months ended March 31, 2023, filed with the SEC on May 11, 2023, the unaudited condensed consolidated financial statements included in its Quarterly Report on Form 10-Q for the three and six months ended June 30, 2023, filed with the SEC on August 9, 2023, and the unaudited condensed consolidated financial statements included in its Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2023, filed with the SEC on November 7, 2023. The Updated Selected Financial Data does not modify or update the disclosures in such reports, other than as indicated to reflect the Reverse Stock Split, and should be read in conjunction with such reports. The information contained in Exhibit 99.1 to this Current Report is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit
No.
  Description
  
104Cover Page Interactive Data File (embedded within the inline XBRL document)


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
PRAXIS PRECISION MEDICINES, INC.
Date: December 1, 2023
By: /s/ Marcio Souza
 Marcio Souza
 Chief Executive Officer

 EX-3.1 2 exhibit31praxis-reversesto.htm EX-3.1 Document

CERTIFICATE OF AMENDMENT
TO
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
PRAXIS PRECISION MEDICINES, INC.

Pursuant to Section 242 of the
General Corporation Law of the State of Delaware
Praxis Precision Medicines, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware,
DOES HEREBY CERTIFY THAT:
1.That the Board of Directors of the Corporation duly adopted resolutions recommending and declaring advisable that the Amended and Restated Certificate of Incorporation of the Corporation, be further amended and that such amendment be submitted to the stockholders of the Corporation for their consideration, as follows:
RESOLVED, that the following paragraph be inserted immediately prior to the first sentence of Article IV of the Amended and Restated Certificate of Incorporation:
“Effective at 5:00 p.m., Eastern time, on the date this Certificate of Amendment to the Amended and Restated Certificate of Incorporation is filed with the Secretary of State of the State of Delaware (the “Effective Time”), a one-for-15 reverse stock split of the Common Stock (as defined below) shall become effective, pursuant to which each 15 shares of Common Stock issued and held of record by each stockholder of the Corporation immediately prior to the Effective Time shall be reclassified and combined into one validly issued, fully paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon the Effective Time and shall represent one share of Common Stock from and after the Effective Time (such reclassification and combination of shares, the “Reverse Stock Split”). No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, (a) with respect to holders of one or more certificates, if any, which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time, upon surrender after the Effective Time of such certificate or certificates, any holder who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Effective Time, shall be entitled to receive a cash payment (the “Fractional Share Payment”) equal to the fraction of which such holder would otherwise be entitled multiplied by the closing price per share of Common Stock on the date of the Effective Time as reported by The Nasdaq Global Select Market (as adjusted to give effect to the Reverse Stock Split); provided that, whether or not fractional shares would be issuable as a result of the Reverse Stock Split shall be determined on the basis of (i) the total number of shares of Common Stock that were issued and outstanding immediately prior to the Effective Time formerly represented by certificates that the holder is at the time surrendering and (ii) the aggregate number of shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificates shall have been reclassified; and (b) with respect to holders of shares of Common Stock in book-entry form in the records of the Corporation’s transfer agent that were issued and outstanding immediately prior to the Effective Time, any holder who would otherwise be entitled to a fractional share of Common Stock as a result of the

|US-DOCS\144527374.4||

Reverse Stock Split (after aggregating all fractional shares), following the Effective Time, shall be entitled to receive the Fractional Share Payment automatically and without any action by the holder.”
2.That, at a meeting of stockholders of the Corporation, the aforesaid amendment was duly adopted by the stockholders of the Corporation.
3.That the aforesaid amendment was duly adopted in accordance with the applicable provisions of Section 242 of the General Corporation Law of the State of Delaware.
IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its President on this 28th day of November 2023.

PRAXIS PRECISION MEDICINES, INC.


By: __/s/ Marcio Souza____________
Name: Marcio Souza
Title: President


|US-DOCS\144527374.4||
 EX-99.1 3 exhibit991reversestocksplit.htm EX-99.1 Document

UNAUDITED SELECTED FINANCIAL DATA (Amounts in thousands, except share and per share data)
Reverse Stock Split
On November 28, 2023, at 5:00 p.m., Eastern Time, Praxis Precision Medicines, Inc. ("Company") effected a 1-for-15 reverse stock split ("Reverse Stock Split") of its common stock, par value $0.0001 per share.
The Company's audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2022, and the Company's unaudited condensed consolidated financial statements included in its Quarterly Report on Form 10-Q for the three month period ended March 31, 2023, three and six month period ended June 30, 2023, and three and nine month period ended September 30, 2023, are presented without giving effect to the Reverse Stock Split.
The following selected financial data has been derived from the Company's audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 7, 2023, and the Company's unaudited condensed consolidated financial statements included in its Quarterly Report on Form 10-Q for the three month period ended March 31, 2023, filed with the SEC on May 11, 2023, the three and six month period ended June 30, 2023, filed with the SEC on August 9, 2023, and for the three and nine month period ended September 30, 2023, filed with the SEC on November 7, 2023, and adjusted to reflect the Reverse Split. The Company's historical results may not be indicative of the results that may be expected in the future.
As Reported (audited):
Years Ended
December 31, 2022December 31, 2021
Net loss$(214,029)$(167,061)
Net loss per share attributable to common stockholders, basic and diluted$(4.64)$(3.94)
Weighted average common shares outstanding, basic and diluted46,096,737 42,454,055 
As Adjusted for the Reverse Stock Split (unaudited):
Years Ended
December 31, 2022December 31, 2021
Net loss$(214,029)$(167,061)
Net loss per share attributable to common stockholders, basic and diluted$(69.65)$(59.03)
Weighted average common shares outstanding, basic and diluted3,073,100 2,830,253 
As Reported (unaudited):
Three Months Ended
March 31, 2023March 31, 2022
Net loss$(37,455)$(68,717)
Net loss per share attributable to common stockholders, basic and diluted$(0.71) $(1.51)
Weighted average common shares outstanding, basic and diluted53,102,907 45,455,179 
As Adjusted for the Reverse Stock Split (unaudited):
Three Months Ended
March 31, 2023March 31, 2022
Net loss$(37,455)$(68,717)
Net loss per share attributable to common stockholders, basic and diluted$(10.58)$(22.68)
Weighted average common shares outstanding, basic and diluted3,540,185 3,030,339 
As Reported (unaudited):


Three Months Ended
June 30, 2023June 30, 2022
Net loss$(34,312)$(60,194)
Net loss per share attributable to common stockholders, basic and diluted$(0.49) $(1.32)
Weighted average common shares outstanding, basic and diluted69,740,719 45,542,600 
As Adjusted for the Reverse Stock Split (unaudited):
Three Months Ended
June 30, 2023June 30, 2022
Net loss$(34,312)$(60,194)
Net loss per share attributable to common stockholders, basic and diluted$(7.38)$(19.83)
Weighted average common shares outstanding, basic and diluted4,649,371 3,036,170 
As Reported (unaudited):
Six Months Ended
June 30, 2023June 30, 2022
Net loss$(71,767)$(128,911)
Net loss per share attributable to common stockholders, basic and diluted$(1.17) $(2.83)
Weighted average common shares outstanding, basic and diluted61,467,774 45,499,131 
As Adjusted for the Reverse Stock Split (unaudited):
Six Months Ended
June 30, 2023June 30, 2022
Net loss$(71,767)$(128,911)
Net loss per share attributable to common stockholders, basic and diluted$(17.51)$(42.50)
Weighted average common shares outstanding, basic and diluted4,097,833 3,033,266 
As Reported (unaudited):
Three Months Ended
September 30, 2023September 30, 2022
Net loss$(24,632)$(43,945)
Net loss per share attributable to common stockholders, basic and diluted$(0.18)$(0.96)
Weighted average common shares outstanding, basic and diluted135,591,429 45,774,376 
As Adjusted for the Reverse Stock Split (unaudited):
Three Months Ended
September 30, 2023September 30, 2022
Net loss$(24,632)$(43,945)
Net loss per share attributable to common stockholders, basic and diluted$(2.72)$(14.40)
Weighted average common shares outstanding, basic and diluted9,039,427 3,051,622 
As Reported (unaudited):


Nine Months Ended
September 30, 2023September 30, 2022
Net loss$(96,399)$(172,856)
Net loss per share attributable to common stockholders, basic and diluted$(1.12)$(3.79)
Weighted average common shares outstanding, basic and diluted86,447,174 45,591,888 
As Adjusted for the Reverse Stock Split (unaudited):
Nine Months Ended
September 30, 2023September 30, 2022
Net loss$(96,399)$(172,856)
Net loss per share attributable to common stockholders, basic and diluted$(16.73)$(56.87)
Weighted average common shares outstanding, basic and diluted5,763,121 3,039,448 

 EX-101.SCH 4 prax-20231128.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 prax-20231128_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Current Fiscal Year End Date Current Fiscal Year End Date Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 6 prax-20231128_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 28, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 28, 2023
Entity Registrant Name PRAXIS PRECISION MEDICINES, INC.
Amendment Flag false
Entity Central Index Key 0001689548
Current Fiscal Year End Date --12-31
Entity Incorporation, State or Country Code DE
Entity File Number 001-39620
Entity Tax Identification Number 47-5195942
Entity Address, Address Line One 99 High Street
Entity Address, Address Line Two 30th Floor
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02110
City Area Code 617
Local Phone Number 300-8460
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol PRAX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 prax-20231128_htm.xml IDEA: XBRL DOCUMENT 0001689548 2023-11-28 2023-11-28 false 0001689548 --12-31 8-K 2023-11-28 PRAXIS PRECISION MEDICINES, INC. DE 001-39620 47-5195942 99 High Street 30th Floor Boston MA 02110 617 300-8460 false false false false Common Stock, $0.0001 par value per share PRAX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

$@5>JQ"(6,P$ "(" / " 9,0 !X;"]W M;W)K8F]O:RYX;6Q02P$"% ,4 " WA(%7)!Z;HJT #X 0 &@ M @ 'S$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M " WA(%799!YDAD! #/ P $P @ '8$@ 6T-O;G1E C;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" B% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://praxismedicines.com/role/Cover Cover Cover 1 false false All Reports Book All Reports prax-20231128.htm prax-20231128.xsd prax-20231128_lab.xml prax-20231128_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "prax-20231128.htm": { "nsprefix": "prax", "nsuri": "http://praxismedicines.com/20231128", "dts": { "inline": { "local": [ "prax-20231128.htm" ] }, "schema": { "local": [ "prax-20231128.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "prax-20231128_lab.xml" ] }, "presentationLink": { "local": [ "prax-20231128_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://praxismedicines.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20231128.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "prax-20231128.htm", "first": true, "unique": true } } }, "tag": { "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://praxismedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001689548-23-000162-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001689548-23-000162-xbrl.zip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end